GLP-1 agonists, such as semaglutide and liraglutide, are widely prescribed for type 2 diabetes and obesity management in the UK. Arachidonic acid, an omega-6 fatty acid, plays a key role in inflammation and metabolic signalling. Emerging research suggests potential interactions between GLP-1 agonists and arachidonic acid metabolism, though no official link is currently recognised by UK regulatory bodies. Understanding these possible mechanisms may provide insight into the broader anti-inflammatory and metabolic effects of GLP-1 therapy. This article explores the current evidence, clinical implications, and what patients should know about these medications.

What Are GLP-1 Agonists and How Do They Work?

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications primarily used to manage type 2 diabetes mellitus and, more recently, obesity. These drugs mimic the action of the naturally occurring incretin hormone GLP-1, which is released from the intestine in response to food intake. Licensed GLP-1 agonists in the UK include semaglutide (Ozempic, Rybelsus, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), lixisenatide (Lyxumia) and exenatide.

The mechanism of action involves binding to GLP-1 receptors on pancreatic beta cells, which stimulates glucose-dependent insulin secretion. This means insulin is released only when blood glucose levels are elevated, thereby reducing the risk of hypoglycaemia compared with some other antidiabetic agents. Additionally, GLP-1 agonists suppress glucagon secretion from pancreatic alpha cells, further contributing to glycaemic control.

Beyond their effects on glucose homeostasis, these medications slow gastric emptying, which prolongs satiety and reduces appetite. This mechanism underpins their efficacy in weight management. GLP-1 receptors are also found in various tissues beyond the pancreas, including the brain, heart, and kidneys, which may explain some of the broader effects observed in clinical trials.

According to NICE guidance (NG28), GLP-1 agonists are recommended for type 2 diabetes in specific circumstances, typically as third-line therapy when other treatments haven't achieved adequate glycaemic control, and in people with a BMI ≥30 kg/m² (adjusted for ethnicity). For weight management, NICE has approved Wegovy (semaglutide 2.4mg, TA875) and Saxenda (liraglutide 3.0mg, TA664) for adults with obesity and at least one weight-related comorbidity, as part of specialist weight management services. GLP-1 agonists should not be used in combination with DPP-4 inhibitors. Common adverse effects include nausea, vomiting, diarrhoea, and injection site reactions, which typically diminish over time with continued use.

Understanding Arachidonic Acid and Its Role in the Body

Arachidonic acid (AA) is a polyunsaturated omega-6 fatty acid that plays a crucial role in cellular signalling and inflammatory responses. It is primarily obtained through the diet—found in meat, eggs, and dairy products—or synthesised endogenously from linoleic acid, another omega-6 fatty acid. Once incorporated into cell membrane phospholipids, arachidonic acid can be released by the enzyme phospholipase A2 in response to various stimuli.

Upon release, arachidonic acid serves as a substrate for several enzymatic pathways that produce bioactive lipid mediators known as eicosanoids. These include:

• Prostaglandins and thromboxanes (via cyclooxygenase enzymes COX-1 and COX-2)

• Leukotrienes (via lipoxygenase enzymes)

• Lipoxins (AA-derived specialised pro-resolving mediators)

These eicosanoids are involved in regulating inflammation, immune responses, blood clotting, and smooth muscle contraction. Whilst arachidonic acid-derived mediators are essential for normal physiological functions—such as protecting the gastric mucosa and maintaining renal blood flow—excessive or dysregulated production can contribute to chronic inflammatory conditions, cardiovascular disease, and metabolic disorders.

In the context of metabolic health, elevated levels of arachidonic acid and its metabolites have been associated with insulin resistance, adipose tissue inflammation, and the pathogenesis of type 2 diabetes. However, the relationship is complex, as some arachidonic acid metabolites also possess anti-inflammatory and insulin-sensitising properties. The balance between pro-inflammatory and pro-resolving pathways appears to be critical in determining overall metabolic outcomes.

The Relationship Between GLP-1 Agonists and Arachidonic Acid

The interaction between GLP-1 agonists and arachidonic acid metabolism is an emerging area of research, though there is currently no official established link recognised by regulatory bodies such as the MHRA or EMA. UK product information (SmPCs) for GLP-1 receptor agonists does not mention effects on arachidonic acid pathways. Preclinical studies suggest that GLP-1 receptor activation may influence lipid metabolism and inflammatory pathways, potentially affecting arachidonic acid levels and its downstream mediators.

Some experimental evidence indicates that GLP-1 agonists may modulate phospholipase A2 activity, the enzyme responsible for releasing arachidonic acid from cell membranes. By influencing this enzyme, GLP-1 agonists could theoretically alter the availability of arachidonic acid for conversion into pro-inflammatory eicosanoids. Additionally, GLP-1 receptor signalling has been shown to affect the expression and activity of cyclooxygenase and lipoxygenase enzymes in certain tissue types, which could further impact the production of prostaglandins and leukotrienes.

Furthermore, weight loss induced by GLP-1 agonists may indirectly influence arachidonic acid metabolism. Adipose tissue is a significant source of inflammatory mediators, and substantial weight reduction typically leads to decreased systemic inflammation and altered fatty acid profiles. Studies have demonstrated that weight loss can reduce circulating levels of pro-inflammatory markers, some of which are derived from arachidonic acid pathways.

It is important to emphasise that whilst these mechanisms are biologically plausible, clinical evidence specifically examining the relationship between GLP-1 agonists and arachidonic acid in humans remains limited. Most current understanding is derived from animal models or in vitro studies, and further research is needed to establish clinically relevant effects and their implications for patient care.

Potential Effects on Inflammation and Metabolic Health

The potential modulation of arachidonic acid metabolism by GLP-1 agonists may have implications for inflammation and metabolic health, though these effects are not yet fully characterised in clinical practice. Chronic low-grade inflammation is a hallmark of obesity and type 2 diabetes, contributing to insulin resistance, endothelial dysfunction, and cardiovascular complications. By potentially influencing arachidonic acid pathways, GLP-1 agonists might exert anti-inflammatory effects beyond their direct actions on glucose and weight control.

Cardiovascular benefits observed with certain GLP-1 agonists in large clinical trials—such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide)—may involve multiple mechanisms, including anti-inflammatory effects. These studies demonstrated reductions in major adverse cardiovascular events, though it remains uncertain whether changes in arachidonic acid metabolism contribute to these outcomes.

Regarding metabolic health, alterations in arachidonic acid-derived mediators could theoretically improve insulin sensitivity and beta-cell function. Some prostaglandins have been shown to impair insulin signalling, whilst others may protect pancreatic beta cells from inflammatory damage. If GLP-1 agonists favourably shift the balance of these mediators, this could represent an additional mechanism contributing to their therapeutic efficacy.

Patient-relevant considerations include the recognition that dietary omega-6 fatty acid intake influences arachidonic acid levels. Whilst there is no current evidence to suggest that patients taking GLP-1 agonists need to modify their omega-6 consumption, maintaining a balanced diet in line with the NHS Eatwell Guide, including sources of omega-3 fatty acids (found in oily fish), may support overall metabolic health. Patients should discuss any significant dietary changes with their healthcare team.

Clinical Considerations for Patients Taking GLP-1 Agonists

For patients prescribed GLP-1 agonists, understanding the broader metabolic effects of these medications can support informed decision-making and adherence to treatment. Whilst the specific interaction with arachidonic acid metabolism is not routinely discussed in clinical consultations, awareness of the anti-inflammatory potential of GLP-1 therapy may provide additional context for their use beyond glucose control.

Common adverse effects that patients should be aware of include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, and constipation. These typically occur during treatment initiation or dose escalation and often improve with continued use. Eating smaller, more frequent meals and staying well-hydrated can help manage these symptoms. For oral semaglutide (Rybelsus), it must be taken on an empty stomach with a small sip of water and patients should wait at least 30 minutes before eating, drinking or taking other oral medicines. Patients should contact their GP if gastrointestinal side effects are severe or persistent.

Serious but rare adverse effects include pancreatitis and gallbladder disease. Patients should seek immediate medical attention if they experience severe, persistent abdominal pain, particularly if accompanied by vomiting, and treatment should be stopped if pancreatitis is suspected. Semaglutide may worsen diabetic retinopathy in some patients, so regular eye screening is important. Severe gastrointestinal symptoms can lead to dehydration and acute kidney injury; patients should maintain fluid intake and seek medical advice if they experience reduced urine output.

Monitoring and follow-up should include regular assessment of glycaemic control (HbA1c), weight, renal function, and cardiovascular risk factors. Patients should be educated about recognising hypoglycaemia, particularly if GLP-1 agonists are used in combination with insulin or sulfonylureas, though the risk is generally low with GLP-1 monotherapy.

Lifestyle modifications remain fundamental to managing type 2 diabetes and obesity. Patients should be encouraged to maintain a balanced diet, engage in regular physical activity, and attend structured education programmes. GLP-1 agonists are not recommended during pregnancy or breastfeeding. Patients should report any suspected side effects via the MHRA Yellow Card scheme.

Frequently Asked Questions